These are the posts from the How we think section that have been tagged with Innovation.
To see all tags used in our posts, click here.
|26th September 2016
The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare. Associate Medical Copywriter Kulveer Singh dives deeper into the technology.
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
|16th August 2016
Associate Medical Copywriter Kulveer Singh explains how biofuel cells work, why they are an exciting alternative to normal battery power, and what the challenges are in implementing their use.
|19th May 2016
Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
|15th March 2016
Blue Latitude Health is now working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, Consultant David Cooney will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
|15th February 2016
Healthcare is not a consumer-driven market where we can assume that patient-centred innovations will automatically influence adoption within doctor communities. In this article, Customer Experience Consultant Anna Tamasi highlights the most common usability and user experience implications that the digitalisation of healthcare poses on doctors' professional lives.
|3rd February 2016
About ten years ago, personalised medicine was a major step forward – tailoring treatments based on individual patient history and information. Fast forward to 2015, and investigating the central dogma of biology is still a major focus of healthcare research.
Consultant David Cooney talks us through what this progress in genomics means for pharma in 2016.
|20th January 2016
Like other sectors, healthcare relies on insight. Therefore, it isn’t immune to the factors that affect the likelihood of a business to reach meaningful insight.
Head of Insight Martine Leroy explains why it's time to rethink what 'insight' means in healthcare.